TRT(SH:600085) Zheng Quan Ri Bao Wang·2025-06-23 13:45Core Viewpoint - Tong Ren Tang has demonstrated resilience and growth in a complex macroeconomic environment, achieving steady revenue growth and maintaining its position as a leading traditional Chinese medicine enterprise [2]. Financial Performance - In 2024, Tong Ren Tang achieved operating revenue of 18.597 billion yuan, representing a year-on-year increase of 4.12% [2]. - The net profit attributable to shareholders of the listed company saw a decline, but the company managed to maintain growth in operating revenue and net assets through targeted strategies [2]. - The total cash dividend proposed for 2024 is 1.371 billion yuan, accounting for 89.86% of the net profit attributable to shareholders, reflecting the company's commitment to shareholder returns [3]. Marketing and Innovation - The company has implemented marketing reforms by increasing retail outlets, integrating online and offline operations, and expanding medical terminal businesses to enhance market competitiveness [2]. - Tong Ren Tang has increased investment in technological innovation to modernize traditional Chinese medicine, laying a solid foundation for long-term development [2][4]. Governance and Communication - The company continues to improve internal management systems and emphasizes the supervisory role of independent directors to ensure scientific and standardized decision-making [3]. - Management actively engages with investors through regular performance briefings and investor communication events to build trust and confidence [3]. Future Development Strategy - Tong Ren Tang plans to focus on high-quality development in the health sector, enhancing market share and brand influence through marketing reforms and brand building [4]. - The company aims to increase research and development investments, promoting the integration of traditional Chinese medicine with modern technology [4]. - Plans include expanding overseas markets and enhancing international brand influence through partnerships with global pharmaceutical companies [4]. Social Responsibility - The company is committed to sustainable development, increasing environmental investments, and engaging in public welfare activities to support the inheritance and development of traditional Chinese medicine [5]. - Future initiatives will focus on accelerating medical industrial upgrades and digital transformation to enhance productivity [5].